View clinical trials related to Cutaneous T-Cell Lymphomas.
Filter by:Hypothesis: Addition of low dose TSEBT to debulk MF/SS either before or during checkpoint blockade with anti-PD-1 pembrolizumab monoclonal antibody therapy will be safe and well tolerated. Primary Objective: • To determine the maximum tolerated dose (MTD) for the combination of total skin electron beam therapy (TSEBT) and pembrolizumab regimen. Secondary Objectives: - To determine the preliminary efficacy of the combination of TSEBT with pembrolizumab. - To determine the impact on patient-reported health-related quality of life outcomes.